Analgesic Infusion for Postoperative Pain

(ON-Q Trial)

This trial aims to determine if a special pain relief method can reduce pain and the need for narcotics after a minimally invasive hysterectomy. It will compare three groups: one receiving a regular saline solution, another receiving a local anesthetic (ropivacaine), and a third receiving both the anesthetic and an anti-inflammatory drug (ketorolac). Women planning to undergo a hysterectomy for non-cancerous reasons, such as fibroids or abnormal bleeding, might be suitable candidates. The trial seeks to find a better way to manage post-surgery pain. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, and this research aims to understand how it benefits more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that ropivacaine is generally safe for adults to use for post-surgery pain. Patients often experience less pain and require fewer strong painkillers. Doses up to 800 mg over 24 hours have not raised major safety concerns.

Studies have also examined the combination of ropivacaine with ketorolac for post-surgery pain management. Administered through a pump, this combination helps maintain low pain levels. Research indicates that this method enhances pain relief without significant safety issues.

Researchers are excited about these treatments for postoperative pain because they offer innovative approaches to pain management using continuous infusion. Unlike traditional oral or injectable pain medications, the ON-Q Pump delivers a steady, targeted infusion of ropivacaine, a local anesthetic, directly at the surgical site, potentially reducing the need for systemic opioids and their side effects. The addition of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), to ropivacaine in one of the treatment arms aims to enhance pain relief by combining anti-inflammatory effects with local anesthesia. This dual-action approach could provide more effective pain control and faster recovery compared to standard treatments, which often rely heavily on opioids.

Research has shown that ropivacaine effectively reduces pain after surgery and lessens the need for opioids. In this trial, some participants will receive a continuous intraperitoneal infusion of ropivacaine, which studies have found significantly improves pain control and speeds recovery. Another group will receive a combination of ropivacaine and ketorolac, offering even better pain relief and further reducing opioid use. This combination has proven more effective in managing pain than treatments without active ingredients. Overall, these treatments offer promising options for post-surgical pain management.¹²⁶⁷⁸